Shares of Shield Therapeutics plc (LON:STX – Get Free Report) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 7.74 and traded as low as GBX 5.70. Shield Therapeutics shares last traded at GBX 5.75, with a volume of 1,676,021 shares trading hands.
Shield Therapeutics Trading Up 6.3%
The firm has a market capitalization of £65.89 million, a price-to-earnings ratio of -3.08 and a beta of 1.88. The firm’s 50 day moving average is GBX 7.66 and its 200 day moving average is GBX 9.10. The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
